About Liz Harris

This author has not yet filled in any details.
So far Liz Harris has created 15 blog entries.
4 May, 2018

CIRCULOGENE’s PD-L1 Expression Test Featured in Clinical Lab Products Magazine

In the latest feature from Clinical Lab Products magazine, experts from First Health, Banner Health and Biodesix Inc. discuss progress and challenges on the way to a blood-based assay for PD-L1. The article, "Overcoming Immune Blockade in [...]

3 May, 2018

The Evolution of In Situ Genetic Technology

This review presents a perspective of in situ genetic technology, including a summary of the methods, principles, endpoints, and applications. The class of in situ genetic techniques has been used for direct measurement of gene functions in specific cell [...]

6 Feb, 2018

Somatic Mutations in Cancer-Free Individuals: A Liquid Biopsy Connection

Somatic Mutations in Cancer-Free Individuals: A Liquid Biopsy Connection Open Acc J Oncol Med 2018. Abstract  Somatic mutations have been perceived as the causal event in the origin of the vast majority of cancers. Advanced massively [...]

11 Jan, 2018

2018 Research Confirms CIRCULOGENE’s Clean Technology

Circulogene's Chief Scientific Officer, Dr. Chen-Hsiung Yeh, authored the latest research findings in ACTA Scientific Cancer Biology, Volume 2, Issue 1. This is the first paper released in 2018, which has important findings that include: Confirming, [...]

31 Oct, 2017

Key Player for Global Liquid Biopsy market

Market Research Future published a research report on "Global Liquid Biopsy Market Research Report- Forecast to 2022" and named Circulogene as one of the top key players for the global liquid biopsy market. Read more: http://www.digitaljournal.com/pr/3540438#ixzz4x60f7KoO [...]

23 May, 2017

CIRCULOGENE Expands Liquid Biopsy Testing Capabilities, Adds Three cfRNA-based NSCLC Tests Supporting Personalized Treatment for Lung Cancer Patients

Circulogene Expands Liquid Biopsy Testing Capabilities, Adds Three cfRNA-based NSCLC Tests Supporting Personalized Treatment for Lung Cancer Patients Droplet-volume, single-tube testing capabilities include both cfDNA- and cfRNA-based tests using NGS and real-time PCR platforms for [...]

27 Feb, 2017

IJRDO-Journal of Biological Science

Sample preparation of circulating cell-free DNA by direct-on-specimen and silica-based methods Andrew Ford, Charmaine Brown, Chen-Hsiung Yeh*  Circulogene Theranostics, Birmingham, USA *Corresponding author  Chen-Hsiung Yeh, PhD Circulogene Theranostics 3125 Independence Dr., Suite 301 Birmingham, AL [...]

12 Jan, 2017

Analysis of Clinical Cancer Gene Panels in Recurrent Ovarian Cancer Patients

The Next Generation Sequencing for this study was performed by Circulogene. The methodology uses cfDNA to utilize a 50 gene panel which offers the opportunity to identify genetic alterations that can be utilized to direct therapy. [...]

22 Jun, 2016

New Research Involving Circulogene’s Liquid Biopsy Further Validates Test’s Cancer Mutation Detection Capabilities

New Research Involving Circulogene’s Liquid Biopsy Further Validates Test’s Cancer Mutation Detection Capabilities Studies show droplet volume liquid biopsy detects new tumor mass earlier than current imaging methods and detects more mutations than tissue biopsy [...]

20 May, 2016

Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference

Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference Research involving Circulogene’s single-drop-volume liquid biopsy assays for real-time monitoring of cancer mutations included in ASCO 2016 BIRMINGHAM, Ala., May 20, 2016 (BUSINESS WIRE) – Circulogene Theranostics, the only biotechnology [...]